BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 7823248)

  • 1. p53 expression, mutation, and allelic deletion in ovarian cancer.
    McManus DT; Yap EP; Maxwell P; Russell SE; Toner PG; McGee JO
    J Pathol; 1994 Nov; 174(3):159-68. PubMed ID: 7823248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of loss of heterozygosity of p53 gene in paraffin-embedded breast cancers by non-isotopic PCR-SSCP.
    Chen YH; Li CD; Yap EP; McGee JO
    J Pathol; 1995 Oct; 177(2):129-34. PubMed ID: 7490678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of heterozygosity and overexpression of the p53 gene in ovarian carcinoma.
    Frank TS; Bartos RE; Haefner HK; Roberts JA; Wilson MD; Hubbell GP
    Mod Pathol; 1994 Jan; 7(1):3-8. PubMed ID: 7909153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma.
    McManus DT; Murphy M; Arthur K; Hamilton PW; Russell SE; Toner PG
    J Pathol; 1996 Jun; 179(2):177-82. PubMed ID: 8758210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
    Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
    Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer.
    Okamoto A; Sameshima Y; Yokoyama S; Terashima Y; Sugimura T; Terada M; Yokota J
    Cancer Res; 1991 Oct; 51(19):5171-6. PubMed ID: 1680546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
    Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
    Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymerase chain reaction-based approaches for detection of allelic loss in the p53 tumor suppressor gene in colon neoplasms.
    Yamaguchi K; Sugano K; Fukayama N; Nakashima Y; Saotome K; Yokoyama T; Yokota T; Ohkura H
    Am J Gastroenterol; 1997 Feb; 92(2):307-12. PubMed ID: 9040212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 gene mutation in relation to p53 protein accumulation in male and female breast cancer.
    Nayak BK; Baral RN; Das BR
    Neoplasma; 1996; 43(5):305-10. PubMed ID: 8996549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of p53 mutations in bilateral breast carcinoma.
    Ackerman J; Baunoch DA; Gimotty P; George J; Lane MA; Dawson PJ
    Mod Pathol; 1995 Apr; 8(3):244-8. PubMed ID: 7617647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allelic loss of chromosome 17p, mutation of the p53 gene, and microsatellite instability in right- and left-sided colorectal cancer.
    Watatani M; Yoshida T; Kuroda K; Ieda S; Yasutomi M
    Cancer; 1996 Apr; 77(8 Suppl):1688-93. PubMed ID: 8608563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Status of the DPC4 tumor suppressor gene in sporadic colon adenocarcinoma of Croatian patients: identification of a novel somatic mutation.
    Popović Hadzija M; Radosevic S; Kovacević D; Lukac J; Hadzija M; Spaventi R; Pavelić K; Kapitanović S
    Mutat Res; 2004 Apr; 548(1-2):61-73. PubMed ID: 15063137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma.
    Kim JW; Cho YH; Kwon DJ; Kim TE; Park TC; Lee JM; Namkoong SE
    Gynecol Oncol; 1995 May; 57(2):199-204. PubMed ID: 7729734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
    Liu FS; Kohler MF; Marks JR; Bast RC; Boyd J; Berchuck A
    Obstet Gynecol; 1994 Jan; 83(1):118-24. PubMed ID: 8272291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutations in ovarian cancer: a late event?
    Mazars R; Pujol P; Maudelonde T; Jeanteur P; Theillet C
    Oncogene; 1991 Sep; 6(9):1685-90. PubMed ID: 1923532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.
    Tolbert DM; Noffsinger AE; Miller MA; DeVoe GW; Stemmermann GN; Macdonald JS; Fenoglio-Preiser CM
    Mod Pathol; 1999 Jan; 12(1):54-60. PubMed ID: 9950163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.